Ryaltris will be marketed and distributed in the US by Hikma Specialty USA
Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company announced its fully owned subsidiary Glenmark Specialty (Switzerland), received FDA approval on its New Drug Application (NDA) for Ryaltris, an innovative, fixed-dose (metered), prescription, combination drug product nasal spray for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and paediatric patients 12 years of age and older in the US.
Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals. “With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms.”
Ryaltris will be marketed and distributed in the US by Hikma Specialty USA, as part of its exclusive licensing agreement with Glenmark Specialty (Switzerland).
